252 related articles for article (PubMed ID: 30824357)
1. Identification of domains within Pfs230 that elicit transmission blocking antibody responses.
Tachibana M; Miura K; Takashima E; Morita M; Nagaoka H; Zhou L; Long CA; Richter King C; Torii M; Tsuboi T; Ishino T
Vaccine; 2019 Mar; 37(13):1799-1806. PubMed ID: 30824357
[TBL] [Abstract][Full Text] [Related]
2. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
[TBL] [Abstract][Full Text] [Related]
3. ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.
Miura K; Deng B; Wu Y; Zhou L; Pham TP; Diouf A; Wu CK; Lee SM; Plieskatt JL; Morin MJ; Long CA
Vaccine; 2019 Apr; 37(15):2073-2078. PubMed ID: 30850239
[TBL] [Abstract][Full Text] [Related]
4. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
[TBL] [Abstract][Full Text] [Related]
5. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity.
Bustamante PJ; Woodruff DC; Oh J; Keister DB; Muratova O; Williamson KC
Parasite Immunol; 2000 Aug; 22(8):373-80. PubMed ID: 10972844
[TBL] [Abstract][Full Text] [Related]
6.
Singh SK; Thrane S; Chourasia BK; Teelen K; Graumans W; Stoter R; van Gemert GJ; van de Vegte-Bolmer MG; Nielsen MA; Salanti A; Sander AF; Sauerwein RW; Jore MM; Theisen M
Front Immunol; 2019; 10():1256. PubMed ID: 31231386
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid.
Vincent AA; Fanning S; Caira FC; Williamson KC
Parasite Immunol; 1999 Nov; 21(11):573-81. PubMed ID: 10583858
[TBL] [Abstract][Full Text] [Related]
8. The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate.
Lee SM; Wu Y; Hickey JM; Miura K; Whitaker N; Joshi SB; Volkin DB; Richter King C; Plieskatt J
Malar J; 2019 Nov; 18(1):356. PubMed ID: 31703583
[TBL] [Abstract][Full Text] [Related]
9. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity.
Tachibana M; Wu Y; Iriko H; Muratova O; MacDonald NJ; Sattabongkot J; Takeo S; Otsuki H; Torii M; Tsuboi T
Clin Vaccine Immunol; 2011 Aug; 18(8):1343-50. PubMed ID: 21715579
[TBL] [Abstract][Full Text] [Related]
10. Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230.
Healer J; McGuinness D; Carter R; Riley E
Parasitology; 1999 Nov; 119 ( Pt 5)():425-33. PubMed ID: 10599074
[TBL] [Abstract][Full Text] [Related]
11. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
Kapulu MC; Da DF; Miura K; Li Y; Blagborough AM; Churcher TS; Nikolaeva D; Williams AR; Goodman AL; Sangare I; Turner AV; Cottingham MG; Nicosia A; Straschil U; Tsuboi T; Gilbert SC; Long CA; Sinden RE; Draper SJ; Hill AV; Cohuet A; Biswas S
Sci Rep; 2015 Jun; 5():11193. PubMed ID: 26063320
[TBL] [Abstract][Full Text] [Related]
13. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins.
Singh K; Burkhardt M; Nakuchima S; Herrera R; Muratova O; Gittis AG; Kelnhofer E; Reiter K; Smelkinson M; Veltri D; Swihart BJ; Shimp R; Nguyen V; Zhang B; MacDonald NJ; Duffy PE; Garboczi DN; Narum DL
Commun Biol; 2020 Jul; 3(1):395. PubMed ID: 32709983
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes.
Williamson KC; Keister DB; Muratova O; Kaslow DC
Mol Biochem Parasitol; 1995 Dec; 75(1):33-42. PubMed ID: 8720173
[TBL] [Abstract][Full Text] [Related]
16. Pfs230: from malaria transmission-blocking vaccine candidate toward function.
Williamson KC
Parasite Immunol; 2003 Jul; 25(7):351-9. PubMed ID: 14521577
[No Abstract] [Full Text] [Related]
17. Human immune recognition of recombinant proteins representing discrete domains of the Plasmodium falciparum gamete surface protein, Pfs230.
Riley EM; Williamson KC; Greenwood BM; Kaslow DC
Parasite Immunol; 1995 Jan; 17(1):11-9. PubMed ID: 7731731
[TBL] [Abstract][Full Text] [Related]
18. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
Kumar R; Angov E; Kumar N
Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
[TBL] [Abstract][Full Text] [Related]
19. A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system.
Lee SM; Hickey JM; Miura K; Joshi SB; Volkin DB; King CR; Plieskatt JL
Sci Rep; 2020 Jan; 10(1):395. PubMed ID: 31942034
[TBL] [Abstract][Full Text] [Related]
20. Functional Characterization and Comparison of
Nikolaeva D; Illingworth JJ; Miura K; Alanine DGW; Brian IJ; Li Y; Fyfe AJ; Da DF; Cohuet A; Long CA; Draper SJ; Biswas S
Mol Cell Proteomics; 2020 Jan; 19(1):155-166. PubMed ID: 29089373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
